Company intelligence / Profile preview

Aanavik Biosciences

Ownership: Private
Development stage: Other

Overview

Aanavik Biosciences appears to be engaged in research and development at the intersection of genetics, personalized medicine, gene editing technologies like CRISPR-Cas9, and advanced computational analysis. The company’s leadership has highlighted contributions to novel cancer gene discovery and early-stage gene therapy development for genetic disorders. No clinical trial results or commercialized products are reported.[4]

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Gene editing (e.g., CRISPR-Cas9)Genomic sequencingComputational genomics tools[4]
Industry: Biotech

Partnerships

Participation/involvement with NIH’s All of Us Research Program as a notable initiative referenced by company leadership; no direct partnerships disclosed.[4]

Beyond the preview

Go deeper on Aanavik Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aanavik Biosciences.

Explore the full profile